Perner S
Institut für Pathologie, Comprehensive Cancer Center, Universitätsklinikum Tübingen, Liebermeisterstr. 8, 72076 Tübingen.
Pathologe. 2010 Oct;31 Suppl 2:121-5. doi: 10.1007/s00292-010-1345-7.
Prostate cancer is a common and clinically heterogeneous disease. Understanding the biology of prostate cancer is necessary to best determinate the risk of disease progression and develop novel therapeutic approaches to prevent or slow down disease progression. The recent discovery and subsequent characterization of recurrent gene rearrangements of ETS genes - most frequently ERG - in the majority of prostate cancers is a milestone in translational prostate cancer research. Although multiple molecular alterations have been detected in prostate cancer, a detailed understanding of gene fusion in prostate cancer should help explain the clinical and biologic diversity in addition to providing a rationale for a molecular sub-classification of the disease. This review describes the path from the identification of common ETS gene rearrangements in prostate cancer to possible applications in the treatment of patients, on to the potential scientific implications arising from their discovery.
前列腺癌是一种常见的且在临床上具有异质性的疾病。了解前列腺癌的生物学特性对于准确确定疾病进展风险以及开发预防或减缓疾病进展的新型治疗方法至关重要。近期在大多数前列腺癌中发现并随后鉴定出ETS基因的复发性基因重排——最常见的是ERG——是前列腺癌转化研究中的一个里程碑。尽管在前列腺癌中已检测到多种分子改变，但对前列腺癌基因融合的详细了解除了可为该疾病的分子亚分类提供理论依据外，还应有助于解释临床和生物学多样性。本综述描述了从在前列腺癌中鉴定常见的ETS基因重排到其在患者治疗中的可能应用，再到因其发现而产生的潜在科学意义的过程。
